Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Delta-Fly Pharma rises for fifth straight day on planned FDA talks for DFP-10917
Delta-Fly Pharma Inc <4598> extended its winning streak to a fifth straight session. After the close on the 16th, the company announced plans to prepare for talks with the US Food and Drug Administration (FDA) regarding conditional marketing approval, following positive Phase 3 trial results for its DFP-10917 monotherapy in patients with relapsed or refractory acute myeloid leukemia.
The company also plans to discuss a Phase 3 trial for a combination therapy of DFP-10917 and Venetoclax (VEN) with the FDA, following promising Phase 1/2 results. The news fueled investor buying interest.
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
Sanrio shares ease on allegations of improper executive compensation
4Cs HD surges for third straight day on solar land, rights sale
Abc shares jump on foray into physical AI robot market
IX Knowledge rebounds on subsidiary's acquisition of systems developer
South Korean KOSPI opens at 6,227.33 (+1.28) on the 17th
Oro shares firm on plan to cancel 2.19% of outstanding shares
Bandai Namco shares firm on share cancellation announcement
SHIGA BANK shares edge higher on reported capital alliance with Senshu Ikeda
SUNCORPORATION shares rise on increased stake by ValueAct Capital
Asahi Diamond Industrial shares jump on upgraded full-year profit forecast as chip demand fuels growth